Skip to main content
Clinical Trials/NCT01141634
NCT01141634
Completed
Phase 2

A Pilot Trial of Homeopathic Treatment for Attention Deficit Hyperactivity Disorder in Children and Adolescents

University of Toronto1 site in 1 country36 target enrollmentJune 2010

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Attention Deficit Hyperactivity Disorder
Sponsor
University of Toronto
Enrollment
36
Locations
1
Primary Endpoint
Conners 3-Parent
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

Attention Deficit Hyperactivity Disorder (ADHD) is a developmental disorder that presents during childhood, and is characterized by developmentally inappropriate levels of inattention and/or hyperactive-impulsive behavior. It is proposed that classical homeopathic treatment can reduce the symptoms of ADHD without serious side effects. This is an open label pilot feasibility study (36 participants). Participants, age 6-16, will consult with a homeopathic practitioner who will select treatments based on classical homeopathy principles. All participants will be assessed on a 4-weekly basis for a total of 36 weeks. The purpose of the study is to assess feasibility of recruitment and patient retention, to obtain pilot data on which to base a sample size calculation for future study, and to identify major safety concerns. The study will use single homeopathic medicines approved for over-the-counter use in Canada. The primary outcome measure will be the validated Conners 3rd Edition - Parent.

Registry
clinicaltrials.gov
Start Date
June 2010
End Date
December 2012
Last Updated
12 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Heather Boon

Principal Investigator

University of Toronto

Eligibility Criteria

Inclusion Criteria

  • Males and females aged 6-16 diagnosed with ADHD of any subtype according to DSM-IV criteria.
  • Mentally competent participants able to adhere to the given protocol and treatments administered as interventions, and able to answer outcome measures.
  • Primary caregiver (parent or guardian) has given informed consent; child participant gives ongoing assent throughout the study.

Exclusion Criteria

  • Changes to participants' medication for ADHD within 6 weeks of study onset.
  • Diagnosis of additional mental health disorder including but not limited to: Conduct Disorder, Autism Spectrum Disorder, Bipolar Disorder, and Major Depressive Disorder. The patient should not have current suicidal or homicidal ideation.
  • Participants should have no history of head injury of seizures, organ system damage and should have an estimated I.Q within the normal range.
  • Pregnancy and Lactation

Outcomes

Primary Outcomes

Conners 3-Parent

Time Frame: 36 weeks

Secondary Outcomes

  • MYMOP2(36 weeks)

Study Sites (1)

Loading locations...

Similar Trials